Pan-Mutant-IDH1 Inhibitor Bay-1436032

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase1	Phase 1	0	0	0	2	0	—	—	May 26, 2016
Leukemia	Phase1	Phase 1	0	0	0	1	0	—	—	Jun 14, 2017

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 16 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
IDH1 R132H1
Pan-Mutant-IDH1 Inhibitor Bay-1436032

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02746081	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	completed	Phase 1	81	BayerINDUSTRY	4	Dec 18, 2024	clinicaltrials
NCT03127735	BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)	completed	Phase 1	27	Bayer